This study evaluates how daily alpha lipoic acid supplementation affects cystine kidney stone
recurrence. Half of the subjects will receive 1200 mg alpha lipoic acid orally daily for
three years, while the other half will receive a placebo. The funding source for this
clinical trial is FDA OOPD.
Phase:
Phase 2
Details
Lead Sponsor:
Thomas Chi, MD University of California, San Francisco
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)